At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Aug 2001 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 15 Jan 1996 Phase-I clinical trials for Cancer in Switzerland (Unknown route)